StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock.

Oragenics Price Performance

Shares of NYSE OGEN opened at $0.19 on Monday. Oragenics has a 1 year low of $0.16 and a 1 year high of $3.43. The firm has a 50-day moving average of $0.24 and a 200 day moving average of $0.30. The stock has a market cap of $4.17 million, a P/E ratio of -0.03 and a beta of 0.87.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.